HK1023942A1 - Self-regulated apoptosis of inflammatory by gene therapy - Google Patents

Self-regulated apoptosis of inflammatory by gene therapy

Info

Publication number
HK1023942A1
HK1023942A1 HK00103061A HK00103061A HK1023942A1 HK 1023942 A1 HK1023942 A1 HK 1023942A1 HK 00103061 A HK00103061 A HK 00103061A HK 00103061 A HK00103061 A HK 00103061A HK 1023942 A1 HK1023942 A1 HK 1023942A1
Authority
HK
Hong Kong
Prior art keywords
gene
apoptosis
tnfalpha
promoter
inflammatory
Prior art date
Application number
HK00103061A
Other languages
English (en)
Inventor
Revati J Tatake
Steven D Marlin
Randall W Barton
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HK1023942A1 publication Critical patent/HK1023942A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
HK00103061A 1997-02-28 2000-05-23 Self-regulated apoptosis of inflammatory by gene therapy HK1023942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3926697P 1997-02-28 1997-02-28
PCT/US1998/003911 WO1998037901A1 (fr) 1997-02-28 1998-02-27 Apoptose auto-regulee de cellules inflammatoires, obtenue par therapie genique

Publications (1)

Publication Number Publication Date
HK1023942A1 true HK1023942A1 (en) 2000-09-29

Family

ID=21904557

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103061A HK1023942A1 (en) 1997-02-28 2000-05-23 Self-regulated apoptosis of inflammatory by gene therapy

Country Status (18)

Country Link
US (1) US6525184B1 (fr)
EP (1) EP0989853B1 (fr)
JP (1) JP2001516210A (fr)
KR (1) KR20000075788A (fr)
CN (1) CN1286530C (fr)
AT (1) ATE362369T1 (fr)
AU (1) AU729063C (fr)
BR (1) BR9807622A (fr)
CA (1) CA2281567A1 (fr)
DE (1) DE69837787D1 (fr)
HK (1) HK1023942A1 (fr)
HU (1) HUP0002317A3 (fr)
IL (1) IL131328A0 (fr)
NZ (1) NZ338013A (fr)
PL (1) PL191586B1 (fr)
RU (1) RU2198683C2 (fr)
TR (1) TR199902068T2 (fr)
WO (1) WO1998037901A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039186A1 (en) * 1997-02-28 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
US6537784B1 (en) * 1998-02-27 2003-03-25 Boehringer Ingelheim Pharmaceuticals Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
WO2000073481A1 (fr) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Techniques et compositions permettant d'abaisser le niveau de facteur de necrose tumorale (tnf) dans les troubles associes au tnf
EP1939300A1 (fr) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
ATE309354T1 (de) * 1999-08-19 2005-11-15 Ct For Translational Res In Ca Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen
US7094891B1 (en) 1999-08-19 2006-08-22 Center For Translation Research In Cancer Replication protein a binding transcriptional factor (RBT1) and uses thereof
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2003033514A1 (fr) 2001-10-19 2003-04-24 Vascular Biogenics Ltd. Constructions de polynucleotides, compositions pharmaceutiques et procedes de regulation negative de l'angiogenese et de therapie anticancereuse
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
IL159894A0 (en) 2001-07-17 2004-06-20 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins
AU2006305550B2 (en) * 2005-10-16 2013-05-02 Yeda Research & Development Co., Ltd Caspase-8 and skin diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01137976A (ja) * 1987-11-20 1989-05-30 Asahi Chem Ind Co Ltd 新規ｄｎａフラグメント
US5792751A (en) 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US7097972B1 (en) * 1995-02-13 2006-08-29 Regents Of The University Of Michigan Method and composition for regulating apoptosis
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
WO1997007828A1 (fr) * 1995-08-30 1997-03-06 The Regents Of The University Of California Therapie pour l'accumulation cellulaire dans les maladies inflammatoires chroniques

Also Published As

Publication number Publication date
HUP0002317A3 (en) 2001-11-28
HUP0002317A2 (hu) 2000-11-28
TR199902068T2 (xx) 1999-12-21
CA2281567A1 (fr) 1998-09-03
CN1286530C (zh) 2006-11-29
EP0989853B1 (fr) 2007-05-16
CN1249688A (zh) 2000-04-05
PL335409A1 (en) 2000-04-25
WO1998037901A1 (fr) 1998-09-03
RU2198683C2 (ru) 2003-02-20
JP2001516210A (ja) 2001-09-25
NZ338013A (en) 2001-05-25
KR20000075788A (ko) 2000-12-26
IL131328A0 (en) 2001-01-28
EP0989853A1 (fr) 2000-04-05
BR9807622A (pt) 2000-02-15
AU6672498A (en) 1998-09-18
US6525184B1 (en) 2003-02-25
EP0989853A4 (fr) 2004-03-17
DE69837787D1 (de) 2007-06-28
AU729063C (en) 2005-02-03
PL191586B1 (pl) 2006-06-30
AU729063B2 (en) 2001-01-25
ATE362369T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
IL131328A0 (en) Self-regulated apoptosis of inflammatory cells by gene therapy
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
CY2311B1 (en) Compounds useful for treating allergic or inflammatory diseases.
ATE410518T1 (de) Kompaktnukleinsäure und ihre verabreichung in zellen
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
MX9602993A (es) Hormona del crecimiento humano.
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
PT912185E (pt) Novas formulacoes farmaceuticas contendo derivados de ester nitrato de esteroides proveitosos como farmacos anti-inflamatorios
NZ331063A (en) Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
HUP0100776A2 (hu) Gyulladásos sejtek önszabályzott apoptózisa génterápiával
AU696644B2 (en) Pharmaceutical compositions and their use, in particular for the treatment of neurodegenerative diseases
DE69730967D1 (en) Human dnase ii
WO1997048795A3 (fr) Compositions et methodes pour traiter des maladies et des troubles lies a l'expression de genes specifiques chez l'homme

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100227